Immunotherapy with a combination of intravenous immune globulin and P4 peptide rescues mice from postinfluenza pneumococcal pneumonia

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 2276-2281

  Weeks, Jenni N ^a   Boyd, Kelli L ^b   Rajam, Gowrisankar ^c   Ades, Edwin W ^c   McCullers, Jonathan A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; P4 PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG UPTAKE; FEMALE; IMMUNOMODULATION; IMMUNOTHERAPY; INFLUENZA; INFLUENZA A; INFLUENZA VIRUS; INFLUENZA VIRUS A; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PHAGOCYTE; PHAGOCYTOSIS; POSTINFLUENZA PNEUMOCOCCAL PNEUMONIA; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA;

ANIMALS; FEMALE; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE;

EID: 79955537039     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00057-11     Document Type: Article

References (25)

1. Centers for Disease Control and Prevention. 2009. Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) - United States, May-August 2009. MMWR Morb. Mortal. Wkly. Rep. 58:1071-1074.
2. Christian, H. A. 1944. The principles and practice of medicine. D. Appleton- Century Company, Inc., New York, NY.
3. Chudwin, D. S. 1989. Prophylaxis and treatment of pneumococcal bacteremia by immune globulin intravenous in a mouse model. Clin. Immunol. Immunopathol. 50:62-71.
4. Domínguez-Cherit, G., et al. 2009. Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 302:1880-1887.
5. Estenssoro, E., et al. 2010. Pandemic 2009 influenza A in Argentina: a study of 337 patients on mechanical ventilation. Am. J. Respir. Crit. Care Med. 182:41-48.
6. Gill, J. R., et al. 2010. Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch. Pathol. Lab. Med. 134:235-243.
7. Jain, S., et al. 2009. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N. Engl. J. Med. 361:1935-1944.
8. Karlström, Å., et al. 2009. Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza. J. Infect. Dis. 199:311-319.
9. Karlström, Å., et al. Toll-like receptor 2 mediates fatal immunopathology in mice during treatment of secondary bacterial pneumonia following influenza. J. Infect. Dis., in press.
10. Kumar, A., et al. 2009. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 302:1872-1879.
11. Manca, F., et al. 1991. Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies. J. Exp. Med. 173:37-48.
12. Mandell, L. A., et al. 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2):S27-S72.
13. Mauad, T., et al. 2010. Lung pathology in fatal novel human influenza A (H1N1) infection. Am. J. Respir. Crit. Care Med. 181:72-79.
14. McAuley, J. L., et al. 2007. Expression of the 1918 influenza A virus PB1-F2 enhances the pathogenesis of viral and secondary bacterial pneumonia. Cell Host Microbe 2:240-249. (Pubitemid 47500821)
15. McCullers, J. A. 2006. Insights into the interaction between influenza virus and pneumococcus. Clin. Microbiol. Rev. 19:571-582.
16. McCullers, J. A., and B. K. English. 2008. Improving therapeutic strategies for secondary bacterial pneumonia following influenza. Future Microbiol. 3:397-404.
17. Melnick, N., et al. 2009. Evaluation of a novel therapeutic approach to treating severe pneumococcal infection using a mouse model. Clin. Vaccine Immunol. 16:806-810.
18. Morens, D. M., J. K. Taubenberger, and A. S. Fauci. 2008. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J. Infect. Dis. 198:962-970.
19. Nimmerjahn, F., and J. V. Ravetch. 2007. Fc-receptors as regulators of immunity. Adv. Immunol. 96:179-204.
20. Palacios, G., et al. 2009. Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS One 4:e8540.
21. Peltola, V. T., K. G. Murti, and J. A. McCullers. 2005. Influenza virus neuraminidase contributes to secondary bacterial pneumonia. J. Infect. Dis. 192:249-257.
22. Rajam, G., et al. 2008. A functional epitope of the pneumococcal surface adhesin A activates nasopharyngeal cells and increases bacterial internalization. Microb. Pathog. 44:186-196.
23. Rajam, G., et al. 2009. A 28-aa pneumococcal surface adhesin A-derived peptide, P4, augments passive immunotherapy and rescues mice from fatal pneumococcal infection. J. Infect. Dis. 199:1233-1238.
24. Shieh, W. J., et al. 2010. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am. J. Pathol. 177:166-175.
25. Smith, M. W., et al. 2007. Induction of pro- and anti-inflammatory molecules in a mouse model of pneumococcal pneumonia after influenza. Comp. Med. 57:82-89.